- Home
- REGN vs SRE Comparison
REGN vs SRE Comparison
Compare REGN & SRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | SRE |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | 15938 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6B | 60.6B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | REGN | SRE |
|---|---|---|
| Price | $648.67 | $92.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $830.16 | $102.08 |
| AVG Volume (30 Days) | 986.6K | ★ 2.9M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 0.55% | ★ 2.84% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | N/A |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $12.45 | $6.42 |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | $96.34 | ★ $28.25 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $73.18 |
| 52 Week High | $821.11 | $101.04 |
Technical Indicators
Market Signals| Indicator | REGN | SRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 52.96 |
| Support Level | $593.21 | $90.20 |
| Resistance Level | $664.00 | $93.74 |
| Average True Range (ATR) | 14.91 | 1.52 |
| MACD | 6.95 | 0.14 |
| Stochastic Oscillator | 86.77 | 62.18 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About SRE DBA Sempra
Sempra serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure Partners, 25% owned by Sempra, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.